VENUSREMPharmaceuticals
Venus Remedies Ltd — Profit & Loss Statement
₹820.05
-1.79%
Venus Remedies Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 4.26 Cr | 0.20 Cr | 25166.40 | 0.00 | — |
| Tax Rate For Calcs | 0.37 | 0.36 | 0.30 | 0.30 | — |
| Normalized EBITDA | 82.86 Cr | 70.63 Cr | 70.34 Cr | 70.14 Cr | — |
| Total Unusual Items | 11.54 Cr | 0.55 Cr | 84000.00 | 0.00 | — |
| Total Unusual Items Excluding Goodwill | 11.54 Cr | 0.55 Cr | 84000.00 | 0.00 | — |
| Net Income From Continuing Operation Net Minority Interest | 45.31 Cr | 28.49 Cr | 26.57 Cr | 40.72 Cr | — |
| Reconciled Depreciation | 22.51 Cr | 26.44 Cr | 32.30 Cr | 33.53 Cr | — |
| Reconciled Cost Of Revenue | 402.19 Cr | 373.19 Cr | 345.36 Cr | 399.77 Cr | — |
| EBITDA | 94.40 Cr | 71.18 Cr | 70.35 Cr | 70.14 Cr | — |
| EBIT | 71.89 Cr | 44.74 Cr | 38.05 Cr | 36.61 Cr | — |
| Net Interest Income | 12.93 Cr | 4.07 Cr | 1.78 Cr | 0.44 Cr | — |
| Interest Expense | 0.07 Cr | 0.09 Cr | 0.12 Cr | 0.20 Cr | — |
| Interest Income | 13.00 Cr | 4.17 Cr | 1.90 Cr | 0.82 Cr | — |
| Normalized Income | 38.03 Cr | 28.14 Cr | 26.56 Cr | 40.72 Cr | — |
| Net Income From Continuing And Discontinued Operation | 45.31 Cr | 28.49 Cr | 26.57 Cr | 40.72 Cr | — |
| Total Expenses | 606.27 Cr | 558.29 Cr | 525.65 Cr | 570.07 Cr | — |
| Rent Expense Supplemental | 0.61 Cr | 0.57 Cr | 0.40 Cr | 0.38 Cr | — |
| Diluted Average Shares | 1.34 Cr | 1.34 Cr | 1.34 Cr | 1.32 Cr | — |
| Basic Average Shares | 1.34 Cr | 1.34 Cr | 1.34 Cr | 1.32 Cr | — |
| Diluted EPS | 33.90 | 21.31 | 19.88 | 30.86 | — |
| Basic EPS | 33.90 | 21.31 | 19.88 | 30.86 | — |
| Diluted NI Availto Com Stockholders | 45.31 Cr | 28.49 Cr | 26.57 Cr | 40.72 Cr | — |
| Net Income Common Stockholders | 45.31 Cr | 28.49 Cr | 26.57 Cr | 40.72 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 45.31 Cr | 28.49 Cr | 26.57 Cr | 40.72 Cr | — |
| Net Income Including Noncontrolling Interests | 45.31 Cr | 28.49 Cr | 26.57 Cr | 40.72 Cr | — |
| Net Income Continuous Operations | 45.31 Cr | 28.49 Cr | 26.57 Cr | 40.72 Cr | — |
| Tax Provision | 26.51 Cr | 16.15 Cr | 11.36 Cr | -4.32 Cr | — |
| Pretax Income | 71.83 Cr | 44.64 Cr | 37.93 Cr | 36.41 Cr | — |
| Other Non Operating Income Expenses | 1.33 Cr | 0.91 Cr | 1.09 Cr | 1.08 Cr | — |
| Special Income Charges | 9.91 Cr | 0.00 | 0.00 | 0.00 | — |
| Net Non Operating Interest Income Expense | 12.93 Cr | 4.07 Cr | 1.78 Cr | 0.44 Cr | — |
| Interest Expense Non Operating | 0.07 Cr | 0.09 Cr | 0.12 Cr | 0.20 Cr | — |
| Interest Income Non Operating | 13.00 Cr | 4.17 Cr | 1.90 Cr | 0.82 Cr | — |
| Operating Income | 41.02 Cr | 33.16 Cr | 27.73 Cr | 28.58 Cr | — |
| Operating Expense | 204.08 Cr | 185.10 Cr | 180.29 Cr | 170.30 Cr | — |
| Other Operating Expenses | 1.92 Cr | 2.17 Cr | 1.45 Cr | 1.35 Cr | — |
| Depreciation And Amortization In Income Statement | 22.51 Cr | 26.44 Cr | 32.30 Cr | 33.53 Cr | — |
| Amortization | 10.52 Cr | 9.05 Cr | 8.76 Cr | 8.76 Cr | — |
| Depreciation Income Statement | 11.99 Cr | 17.40 Cr | 23.53 Cr | 24.77 Cr | — |
| Research And Development | 18.08 Cr | 15.84 Cr | 22.88 Cr | 23.03 Cr | — |
| Selling General And Administration | 81.06 Cr | 78.58 Cr | 64.06 Cr | 57.36 Cr | — |
| Selling And Marketing Expense | 65.74 Cr | 65.81 Cr | 52.51 Cr | 48.95 Cr | — |
| General And Administrative Expense | 15.31 Cr | 12.77 Cr | 11.56 Cr | 8.41 Cr | — |
| Rent And Landing Fees | 0.61 Cr | 0.57 Cr | 0.40 Cr | 0.38 Cr | — |
| Gross Profit | 245.10 Cr | 218.26 Cr | 208.02 Cr | 198.88 Cr | — |
| Cost Of Revenue | 402.19 Cr | 373.19 Cr | 345.36 Cr | 399.77 Cr | — |
| Total Revenue | 647.29 Cr | 591.45 Cr | 553.38 Cr | 598.65 Cr | — |
| Operating Revenue | 647.29 Cr | 591.45 Cr | 553.38 Cr | 598.65 Cr | — |
| Total Other Finance Cost | — | — | 0.14 Cr | 0.18 Cr | 6.01 Cr |
| Other Special Charges | — | — | — | — | -23.44 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Venus Remedies Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.